##common.pageHeaderLogo.altText##

Original article

Vol. 155 No. 10 (2025)

Cardiac amyloidosis in a Swiss autopsy cohort – distribution and clinical relevance

Cite this as:
Swiss Med Wkly. 2025;155:4541
Published
01.10.2025

Summary

AIMS: Cardiac amyloidosis (CA) characterised by myocardial amyloid accumulation is likely underdiagnosed. The distribution and extent of myocardial amyloid deposits remain unclear. With the emergence of disease-modifying drugs for ATTR and AL amyloidoses, early detection has become increasingly important. We aim to determine the frequency, clinical relevance and distribution of amyloid subtypes in cardiac amyloidosis in an autopsy cohort.

METHODS: We retrospectively analysed consecutive unselected adult autopsies with cardiac amyloidosis over 10 years (January 2014 – December 2023). Two pathologists applied a biventricular semi-quantitative scoring system for interstitial and vascular amyloid deposits. Histopathological findings were correlated with ante mortem clinical data.

RESULTS: Cardiac amyloidosis was found in 104 of 1972 autopsies (5%) with 91% neither diagnosed nor suspected ante mortem based on documentation in digital medical records. Ninety-eight patients (94%) had amyloid transthyretin-cardiac amyloidosis (ATTR-CA) and six (6%) amyloid light chain-cardiac amyloidosis (AL-CA). AL-CA patients were younger than ATTR-CA patients (mean ± SD: 73.2 ± 15.3 vs 84.2 ± 8.1, p = 0.006) and systemic amyloidosis was more frequent (100% vs 38%, p = 0.003). Female patients (40.4%) were significantly older (mean ± SD: 85.8 ± 8.1 years) than males (82.0 ± 9.2 years, p = 0.23), and male sex was associated with clinical suspicion and diagnosis (88.9% in males vs 11.1% in females, p = 0.06). A high vascular amyloid score correlated with systemic amyloidosis (left ventricle, p = 0.003; right ventricle, p = 0.013). Right ventricular amyloid burden was strongly linked to clinical suspicion and detection (p = 0.001).

CONCLUSIONS: Our autopsy analysis found that most cardiac amyloidosis cases were undiagnosed ante mortem, especially ATTR-CA in older patients with less systemic involvement. Underdiagnosis was more pronounced in females. Our findings suggest that high vascular amyloid burden contributes to systemic amyloidosis and links right ventricular amyloid to clinical suspicion and detection.

References

  1. 1. Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2021 Apr;42(16):1554–68. doi: https://doi.org/10.1093/eurheartj/ehab072
  2. 2. Bloom MW, Gorevic PD. Cardiac Amyloidosis. Ann Intern Med. 2023 Mar;176(3):ITC33–48. doi: https://doi.org/10.7326/AITC202303210
  3. 3. Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C, et al.; ESC Scientific Document Group. 2023 ESC Guidelines for the management of cardiomyopathies. Eur Heart J. 2023 Oct;44(37):3503–626. doi: https://doi.org/10.1093/eurheartj/ehad194
  4. 4. Buxbaum JN, Eisenberg DS, Fändrich M, McPhail ED, Merlini G, Saraiva MJ, et al. Amyloid nomenclature 2024: update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee. Amyloid. 2024 Dec;31(4):249–56. doi: https://doi.org/10.1080/13506129.2024.2405948
  5. 5. Ruberg FL, Maurer MS. Cardiac Amyloidosis Due to Transthyretin Protein: A Review. JAMA. 2024 Mar;331(9):778–91. doi: https://doi.org/10.1001/jama.2024.0442
  6. 6. Martinez-Naharro A, Hawkins PN, Fontana M. Cardiac amyloidosis. Clin Med (Lond). 2018 Apr;18 Suppl 2:s30–5. doi: https://doi.org/10.7861/clinmedicine.18-2-s30
  7. 7. Brouwers S, Heimgartner R, Laptseva N, Aguzzi A, Ehl NF, Fehr T, et al. Historic characteristics and mortality of patients in the Swiss Amyloidosis Registry. Swiss Med Wkly. 2024 Feb;154(2):3485. doi: https://doi.org/10.57187/s.3485
  8. 8. Palladini G, Kastritis E, Maurer MS, Zonder J, Minnema MC, Wechalekar AD, et al. Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA. Blood. 2020 Jul;136(1):71–80. doi: https://doi.org/10.1182/blood.2019004460
  9. 9. Grogan M, Scott CG, Kyle RA, Zeldenrust SR, Gertz MA, Lin G, et al. Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System. J Am Coll Cardiol. 2016 Sep;68(10):1014–20. doi: https://doi.org/10.1016/j.jacc.2016.06.033
  10. 10. Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet. 2016 Jun;387(10038):2641–54. doi: https://doi.org/10.1016/S0140-6736(15)01274-X
  11. 11. Wang S, Peng W, Pang M, Mao L, Peng D, Yu B, et al. Clinical Profile and Prognosis of Hereditary Transthyretin Amyloid Cardiomyopathy: A Single-Center Study in South China. Front Cardiovasc Med. 2022 Jun;9:900313. doi: https://doi.org/10.3389/fcvm.2022.900313
  12. 12. Conceição I, Damy T, Romero M, Galán L, Attarian S, Luigetti M, et al. Early diagnosis of ATTR amyloidosis through targeted follow-up of identified carriers of TTR gene mutations. Amyloid. 2019 Mar;26(1):3–9. doi: https://doi.org/10.1080/13506129.2018.1556156
  13. 13. Schwotzer R, Flammer AJ, Gerull S, Pabst T, Arosio P, Averaimo M, et al. Expert recommendation from the Swiss Amyloidosis Network (SAN) for systemic AL-amyloidosis. Swiss Med Wkly. 2020 Dec;150(4950):w20364. doi: https://doi.org/10.4414/smw.2020.20364
  14. 14. Castaño A, Narotsky DL, Hamid N, Khalique OK, Morgenstern R, DeLuca A, et al. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J. 2017 Oct;38(38):2879–87. doi: https://doi.org/10.1093/eurheartj/ehx350
  15. 15. Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019 Jun;73(22):2872–91. doi: https://doi.org/10.1016/j.jacc.2019.04.003
  16. 16. Dunlay SM, Roger VL, Redfield MM. Epidemiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2017 Oct;14(10):591–602. doi: https://doi.org/10.1038/nrcardio.2017.65
  17. 17. AbouEzzeddine OF, Davies DR, Scott CG, Fayyaz AU, Askew JW, McKie PM, et al. Prevalence of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction. JAMA Cardiol. 2021 Nov;6(11):1267–74. doi: https://doi.org/10.1001/jamacardio.2021.3070
  18. 18. Clerc OF, Datar Y, Cuddy SA, Bianchi G, Taylor A, Benz DC, et al. Prognostic Value of Left Ventricular 18F-Florbetapir Uptake in Systemic Light-Chain Amyloidosis. JACC Cardiovasc Imaging. 2024 Aug;17(8):911–22. doi: https://doi.org/10.1016/j.jcmg.2024.05.002
  19. 19. Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012 Mar;30(9):989–95. doi: https://doi.org/10.1200/JCO.2011.38.5724
  20. 20. Palladini G, Milani P. Diagnosis and Treatment of AL Amyloidosis. Drugs. 2023 Feb;83(3):203–16. doi: https://doi.org/10.1007/s40265-022-01830-z
  21. 21. Lachmann HJ, Goodman HJ, Gilbertson JA, Gallimore JR, Sabin CA, Gillmore JD, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med. 2007 Jun;356(23):2361–71. doi: https://doi.org/10.1056/NEJMoa070265
  22. 22. Maccio U, Meier CA, Reinehr M, Ruschitzka F, Schüpbach R, Moch H, et al. Clinically Undiagnosed Diseases in Autopsies: Frequency and Risk Factors. Arch Pathol Lab Med. 2025 Jan;149(1):60–6. doi: https://doi.org/10.5858/arpa.2023-0429-OA
  23. 23. Bajwa F, O’Connor R, Ananthasubramaniam K. Epidemiology and clinical manifestations of cardiac amyloidosis. Heart Fail Rev. 2022 Sep;27(5):1471–84. doi: https://doi.org/10.1007/s10741-021-10162-1
  24. 24. Aimo A, Merlo M, Porcari A, Georgiopoulos G, Pagura L, Vergaro G, et al. Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta-analysis of screening studies. Eur J Heart Fail. 2022 Dec;24(12):2342–51. doi: https://doi.org/10.1002/ejhf.2532
  25. 25. Tanskanen M, Peuralinna T, Polvikoski T, Notkola IL, Sulkava R, Hardy J, et al. Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study. Ann Med. 2008;40(3):232–9. doi: https://doi.org/10.1080/07853890701842988
  26. 26. Mohammed SF, Mirzoyev SA, Edwards WD, Dogan A, Grogan DR, Dunlay SM, et al. Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. JACC Heart Fail. 2014 Apr;2(2):113–22. doi: https://doi.org/10.1016/j.jchf.2013.11.004
  27. 27. Porcari A, Bussani R, Merlo M, Varrà GG, Pagura L, Rozze D, et al. Incidence and Characterization of Concealed Cardiac Amyloidosis Among Unselected Elderly Patients Undergoing Post-mortem Examination. Front Cardiovasc Med. 2021 Nov;8:749523. doi: https://doi.org/10.3389/fcvm.2021.749523
  28. 28. Tateishi Y, Yamada Y, Katsuki M, Nagata T, Yamamoto H, Kohashi K, et al. Pathological review of cardiac amyloidosis using autopsy cases in a single Japanese institution. Pathol Res Pract. 2021 Nov;227:153635. doi: https://doi.org/10.1016/j.prp.2021.153635
  29. 29. Ueda M, Sekijima Y, Koike H, Yamashita T, Yoshinaga T, Ishii T, et al. Monitoring of asymptomatic family members at risk of hereditary transthyretin amyloidosis for early intervention with disease-modifying therapies. J Neurol Sci. 2020 Jul;414:116813. doi: https://doi.org/10.1016/j.jns.2020.116813
  30. 30. Maccio U, Wicki A, Ruschitzka F, Beuschlein F, Wolleb S, Varga Z, et al. Frequency and Consequences of Immune Checkpoint Inhibitor-Associated Inflammatory Changes in Different Organs: An Autopsy Study Over 13 -Years. Mod Pathol. 2025 Apr;38(4):100683. doi: https://doi.org/10.1016/j.modpat.2024.100683
  31. 31. Maleszewski JJ. Cardiac amyloidosis: pathology, nomenclature, and typing. Cardiovasc Pathol. 2015;24(6):343–50. doi: https://doi.org/10.1016/j.carpath.2015.07.008
  32. 32. Linke RP. On typing amyloidosis using immunohistochemistry. Detailled illustrations, review and a note on mass spectrometry. Prog Histochem Cytochem. 2012 Aug;47(2):61–132. doi: https://doi.org/10.1016/j.proghi.2012.03.001
  33. 33. Puth MT, Neuhäuser M, Ruxton GD. Effective use of Spearman’s and Kendall’s correlation coefficients for association between two measured traits. Anim Behav. 2015;102:77–84. doi: https://doi.org/10.1016/j.anbehav.2015.01.010
  34. 34. Maccio U, Meier CA, Reinehr M, Ruschitzka F, Schupbach R, Moch H, et al. Clinically Undiagnosed Diseases in Autopsies: Frequency and Risk Factors. Arch Pathol Lab Med. 2024.
  35. 35. Fontana M, Ćorović A, Scully P, Moon JC. Myocardial Amyloidosis: The Exemplar Interstitial Disease. JACC Cardiovasc Imaging. 2019 Nov;12(11 Pt 2):2345–56. doi: https://doi.org/10.1016/j.jcmg.2019.06.023
  36. 36. de Marneffe N, Dulgheru R, Ancion A, Moonen M, Lancellotti P. Cardiac amyloidosis: a review of the literature. Acta Cardiol. 2022 Oct;77(8):683–92. doi: https://doi.org/10.1080/00015385.2021.1992990
  37. 37. Mirioglu S, Uludag O, Hurdogan O, Kumru G, Berke I, Doumas SA, et al. AA Amyloidosis: A Contemporary View. Curr Rheumatol Rep. 2024 Jul;26(7):248–59. doi: https://doi.org/10.1007/s11926-024-01147-8
  38. 38. Yun S, Palladini G, Anderson LJ, Cariou E, Wang R, Angeli FS, et al. International prevalence of transthyretin amyloid cardiomyopathy in high-risk patients with heart failure and preserved or mildly reduced ejection fraction. Amyloid. 2024 Dec;31(4):291–301. doi: https://doi.org/10.1080/13506129.2024.2398446
  39. 39. Rubin J, Maurer MS. Cardiac Amyloidosis: Overlooked, Underappreciated, and Treatable. Annu Rev Med. 2020 Jan;71(1):203–19. doi: https://doi.org/10.1146/annurev-med-052918-020140
  40. 40. Datar Y, Clerc OF, Cuddy SA, Kim S, Taylor A, Neri JC, et al. Quantification of right ventricular amyloid burden with 18F-florbetapir positron emission tomography/computed tomography and its association with right ventricular dysfunction and outcomes in light-chain amyloidosis. Eur Heart J Cardiovasc Imaging. 2024 Apr;25(5):687–97. doi: https://doi.org/10.1093/ehjci/jead350
  41. 41. Ozbay B, Satyavolu BS, Rearick C, Soman P, Katz WE, Sezer A, et al. Right Ventricular Strain Improves the Echocardiographic Diagnosis and Risk Stratification of Transthyretin Cardiac Amyloidosis Among Other Phenotypes of Left Ventricular Hypertrophy. J Am Soc Echocardiogr. 2024 Oct;37(10):947–59. doi: https://doi.org/10.1016/j.echo.2024.06.006
  42. 42. Istratoaie S, Bourg C, Lee KC, Marut B, Antonelli J, L’official G, et al. Right ventricular free wall strain predicts transthyretin amyloidosis prognosis as well as biomarker-based staging systems. Eur Heart J Cardiovasc Imaging. 2025 Jan;26(2):239–48. doi: https://doi.org/10.1093/ehjci/jeae242
  43. 43. Eckstein J, Körperich H, Weise Valdés E, Sciacca V, Paluszkiewicz L, Burchert W, et al. CMR-based right ventricular strain analysis in cardiac amyloidosis and its potential as a supportive diagnostic feature. Int J Cardiol Heart Vasc. 2022 Dec;44:101167. doi: https://doi.org/10.1016/j.ijcha.2022.101167
  44. 44. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al.; ACC/AHA Joint Committee Members. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022 May;145(18):e895–1032. doi: https://doi.org/10.1161/CIR.0000000000001063
  45. 45. Nagy D, Révész K, Peskó G, Varga G, Horváth L, Farkas P, et al. Cardiac Amyloidosis with Normal Wall Thickness: Prevalence, Clinical Characteristics and Outcome in a Retrospective Analysis. Biomedicines. 2022 Jul;10(7):1765. doi: https://doi.org/10.3390/biomedicines10071765
  46. 46. Zampiccoli E, Barthelmes J, Kreysing L, Nägele MP, Nebunu D, Haider T, et al. Eyes on amyloidosis: microvascular retinal dysfunction in cardiac amyloidosis. ESC Heart Fail. 2022 Apr;9(2):1186–94. doi: https://doi.org/10.1002/ehf2.13792
  47. 47. Chen D, Zhang C, Parikh N, Merkler AE, Navi BB, Fink ME, et al. Association Between Systemic Amyloidosis and Intracranial Hemorrhage. Stroke. 2022 Mar;53(3):e92–3. doi: https://doi.org/10.1161/STROKEAHA.121.038451
  48. 48. Clerc OF, Cuddy SA, Jerosch-Herold M, Benz DC, Katznelson E, Canseco Neri J, et al. Myocardial Characteristics, Cardiac Structure, and Cardiac Function in Systemic Light-Chain Amyloidosis. JACC Cardiovasc Imaging. 2024 Nov;17(11):1271–86. doi: https://doi.org/10.1016/j.jcmg.2024.05.004
  49. 49. Stroo E, Koopman M, Nollen EA, Mata-Cabana A. Cellular Regulation of Amyloid Formation in Aging and Disease. Front Neurosci. 2017 Feb;11:64. doi: https://doi.org/10.3389/fnins.2017.00064
  50. 50. Cannata’ A, Merlo M, Artico J, Gentile P, Camparini L, Cristallini J, et al. Cardiovascular aging: the unveiled enigma from bench to bedside. J Cardiovasc Med (Hagerstown). 2018 Oct;19(10):517–26. doi: https://doi.org/10.2459/JCM.0000000000000694
  51. 51. Pras A, Nollen EA. Regulation of Age-Related Protein Toxicity. Front Cell Dev Biol. 2021 Mar;9:637084. doi: https://doi.org/10.3389/fcell.2021.637084
  52. 52. Ichimata S, Hata Y, Hirono K, Yamaguchi Y, Nishida N. Clinicopathological features of clinically undiagnosed sporadic transthyretin cardiac amyloidosis: a forensic autopsy-based series. Amyloid. 2021 Jun;28(2):125–33. doi: https://doi.org/10.1080/13506129.2021.1882979
  53. 53. Tan L, Byard RW. Cardiac amyloid deposition and the forensic autopsy - A review and analysis. J Forensic Leg Med. 2024 Apr;103:102663. doi: https://doi.org/10.1016/j.jflm.2024.102663
  54. 54. D’Errico S, Mazzanti A, Baldari B, Maiese A, Frati P, Fineschi V. Sudden death in lambda light chain AL cardiac amyloidosis: a review of literature and update for clinicians and pathologists. Int J Clin Exp Pathol. 2020 Jul;13(7):1474–82.
  55. 55. Rodewald AK, Bode P, Cathomas G, Moch H. [Clinical autopsies in Switzerland: A status report]. Pathologe. 2017 Sep;38(5):416–21. doi: https://doi.org/10.1007/s00292-017-0323-8